Ignite Creation Date:
2025-12-24 @ 9:36 PM
Ignite Modification Date:
2025-12-30 @ 9:27 PM
Study NCT ID:
NCT00423332
Status:
COMPLETED
Last Update Posted:
2017-02-02
First Post:
2007-01-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-01
Start Date Type:
None
Primary Completion Date:
2008-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10
Completion Date Type:
ACTUAL
First Submit Date:
2007-01-16
First Submit QC Date:
None
Study First Post Date:
2007-01-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-04-03
Results First Submit QC Date:
None
Results First Post Date:
2012-09-06
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2011-04-12
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2016-12-08
Last Update Post Date:
2017-02-02
Last Update Post Date Type:
ESTIMATED